Avinger

Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat. The company was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avinger reports Q1 revenue growth, secures China partnership for expansion

Avinger's Q1 2024 performance showed revenue growth but challenges in profitability.
Strategic partnerships and product development present growth opportunities.
Financial restructuring and cost management are crucial for future success.

Avinger reports improved Q3 performance and strategic growth initiatives

Avinger's Q3 2024 performance showed operational improvements and cost-saving initiatives, leading to reduced losses.
The company's strategic partnerships and focus on innovation position them for growth opportunities in the medical device market.
While challenges persist, Avinger's progress in commercialization and partnerships signal a path towards financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AcelRx Pharmaceuticals

Genocea Biosciences

Gossamer Bio Inc

Village Farms International

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Bet on Rising P/E Investing  With These Top 5 Stocks

Alexion Pharma

CyberArk Software

Organovo Hlds

Qualys

Bet on these top-ranked stocks with rising P/E for outsized gains.

What Bargain Hunting ? Tap 5 Stocks With Rising P/E

Avinger, Inc. (AVGR) CEO Jeffrey Soinski on Q3 2019 Results - Earnings Call Transcript

Check Point Software Technologies

ServiceNow

TripAdvisor

Try Rising P/E Investing With 5 Top-Ranked Stocks

Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Avinger (AVGR) Upgraded to Strong Buy: What Does It Mean for the Stock?

AECOM

Brunswick

Boot Barn Hlds

Top Ranked Momentum Stocks to Buy for October 24th

SPS Commerce

Skyworks Solutions

Varian Medical Systems

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

REDWOOD CITY, Calif., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 572,033 additional shares to cover over-allotments, if any. The shares were offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at   www.sec.go v  .

Avinger Closes $4.5 Million Equity Offering

REDWOOD CITY, Calif., Aug.  21, 2019  (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures. The Company may also use a portion of the net proceeds to acquire complementary products, technologies or businesses; however, the Company currently has no agreements or commitments to complete any such transactions.

Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock

REDWOOD CITY, Calif., Aug.  21, 2019  (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures. The Company may also use a portion of the net proceeds to acquire complementary products, technologies or businesses; however, the Company currently has no agreements or commitments to complete any such transactions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Avinger Announces Proposed Underwritten Public Offering of Common Stock

Avinger's (AVGR) CEO Jeff Soinski on Q2 2019 Results - Earnings Call Transcript

Is  (AVGR) Outperforming Other Medical Stocks This Year?

Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2019 Results - Earnings Call Transcript

Is Avinger (AVGR) Outperforming Other Medical Stocks This Year?

Avinger (AVGR) closed at $0.58 in the latest trading session, marking a -0.62% move from the prior day.

Avinger (AVGR) Dips More Than Broader Markets: What You Should Know

Automatic Data Processing

Chipotle

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 9th.

Top Ranked Momentum Stocks to Buy for April 9th - 2019

News for Avinger Stock (AVGR)